Related Experiment Video
Updated: Jul 16, 2026

11:42
Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells
Published on: April 7, 2017
Local Recurrence and Metastasis Define Distinct Recurrence Phenotypes in Soft Tissue Sarcoma
Markus Schärer1,2, Philip Heesen3, Gabriela Studer4,5
1Sarcoma Service, Department of Orthopedics and Trauma, Kantonsspital Winterthur, 8400 Winterthur, Switzerland.
Cancers
|July 15, 2026
Summary
Recurrence in soft tissue sarcomas (STS) involves distinct phenotypes based on local and metastatic disease interactions. Understanding these patterns is crucial for predicting outcomes and managing STS effectively.
Area of Science:
- Oncology
- Surgical Oncology
- Sarcoma Research
Background:
- Soft tissue sarcomas (STS) exhibit clinical heterogeneity.
- Local recurrence (LR) and metastasis are often analyzed separately.
- The interaction between local and metastatic disease in STS recurrence requires further investigation.
Purpose of the Study:
- To define distinct recurrence phenotypes in STS based on the interplay of local and metastatic disease.
- To analyze tumor characteristics, treatment, surgical factors, and event sequences across different recurrence phenotypes.
- To elucidate the clinical significance of local recurrence within the context of metastatic disease.
Main Methods:
- Analysis of prospective registry data from 668 patients with histologically confirmed STS.
- Stratification of patients into four recurrence phenotypes: no event, metastasis only, LR only, and combined LR and metastasis.
- Statistical analysis of tumor grade, location, recurrence timing, and event sequence.
Main Results:
- Recurrence phenotypes were distributed as: no event (52.2%), metastasis only (23.8%), LR only (13.5%), and combined (10.5%).
- High-grade tumors (G3) were significantly more frequent in metastasis-only and combined recurrence phenotypes.
- Early LR was more common in the combined phenotype, while late LR predominated in isolated LR cases. High grade and axial location independently predicted combined recurrence.
Conclusions:
- STS recurrence is characterized by distinct phenotypes resulting from the interaction between local and metastatic disease.
- The clinical impact of local recurrence is significantly influenced by its association with metastatic events.
- Identifying these recurrence phenotypes offers a more nuanced understanding for improved STS management.
Related Concept Videos
Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Metastasis
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Cancer Stem Cells and Tumor Maintenance
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancers Originate from Somatic Mutations in a Single Cell
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...

